Next Article in Journal
Bactericidal Action of Shrimp Shell Chitooligosaccharide Conjugated with Epigallocatechin Gallate (COS-EGCG) against Listeria monocytogenes
Next Article in Special Issue
Protective Effect of Hawthorn Fruit Extract against High Fructose-Induced Oxidative Stress and Endoplasmic Reticulum Stress in Pancreatic β-Cells
Previous Article in Journal
Rapid and Simultaneous Detection of Aflatoxin B1, Zearalenone, and T-2 Toxin in Medicinal and Edible Food Using Gold Immunochromatographic Test Strip
Previous Article in Special Issue
Investigation of the Effect of Rice Bran Content on the Antioxidant Capacity and Related Molecular Conformations of Plant-Based Simulated Meat Based on Raman Spectroscopy
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Computer-Aided Screening and Revealing Action Mechanism of Green Tea Polyphenols Intervention in Alzheimer’s Disease

Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, School of Life Science, Jilin University, 2699 Qianjin Street, Changchun 130012, China
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Foods 2023, 12(3), 635; https://doi.org/10.3390/foods12030635
Submission received: 13 December 2022 / Revised: 18 January 2023 / Accepted: 25 January 2023 / Published: 2 February 2023

Abstract

:
The accumulation of cross-β-sheet amyloid fibrils is a hallmark of the neurodegenerative process of Alzheimer’s disease (AD). Although it has been reported that green tea substances such as epicatechin (EC), epicatechin-3-gallate (ECG), epigallocatechin (EGC) and epigallocatechin-3-gallate (EGCG) could alleviate the symptoms of AD and other neurodegenerative diseases, the pharmacological mechanism remains largely unexplored. This study aimed to reveal the underlying mechanism of EC, ECG, EGC and EGCG in AD using a computer-aided screening strategy. Our results showed that the four tea polyphenols interfered with the signaling pathways of AD via calcium signaling channels, neurodegeneration-multiple disease signal pathways and others. We also identified the key residues of the interaction between VEGFA and the four active components, which included Glu64 and Phe36. Overall, we have provided valuable insights into the molecular mechanism of tea polyphenols, which could be used as a reference to improve therapeutic strategies against AD.

1. Introduction

Alzheimer’s disease (AD) is a prevalent neurodegenerative disorder that significantly affects the daily activities and quality of life of the elderly population [1,2,3,4,5,6,7,8]. Its etiology has been reported to be multifactorial, including family history and genetics, advanced age, head trauma, cognitive impairment, etc. [1,2,3,4,5,6,7,8]. Currently, there are several hypotheses describing the pathogenesis of AD, such as β-amyloid (Aβ) deposition [9,10,11,12] and tau hyperphosphorylation [13], which are reported to cause extracellular amyloid plaques and neurofibrillary tangle in brain neurons [14]. Despite advancements in pharmacology, the incidence of AD has been increasing as there is neither a cure nor treatment to alter its progression, and existing anti-AD drugs are clinically limited due to having poor efficacy and causing significant adverse reactions [15,16].
The health benefits of tea have been recognized worldwide [17,18,19]. Most epidemiological studies suggest that drinking two to three cups of tea daily, particularly green or black tea, could be a natural complementary therapy for neurodegenerative diseases as it can reduce the risk of cognitive impairment [20]. In addition, there is abundant literature on the neuroprotective effects of tea, such as improved learning and memory, reduced risk of toxicity and good synergy with anti-AD medications [21,22,23].
The regulating effects of the active ingredients in tea on AD can be divided into direct and indirect effects. The active ingredients of tea can directly exert their effects on the nervous system and the immune system following intestinal absorption. For instance, tea polyphenols, in particular, epicatechin (EC) [24], epicatechin-3-gallate (ECG) [25], epigallocatechin (EGC) [26] and epigallocatechin- 3-gallate (EGCG) [27], have been extensively reported to offer protection against neurodegenerative diseases such as AD and Parkinson’s disease [28,29,30,31]. Most existing related studies have focused on these polyphenols’ antioxidant and anti-inflammatory properties [24,25,26,27]. Furthermore, EGCG, the major constituent of green tea, has been confirmed to inhibit Aβ fibril formation [32]. However, the underlying mechanism of the inhibition of Aβ fibril formation by these polyphenols has been seldom reported.
Network pharmacology is an interactive network based on the concept of “disease-gene-target-compounds” that can be used to assess the potential effects of tea polyphenols (especially EC [24], ECG [25], EGC [26] and EGCG [27]) in patients with AD from a systematic and comprehensive perspective to reveal the complex underlying mechanisms of these active compounds [33,34,35]. On the basis of this concept, we performed a computer-aided screening strategy to explore the mechanism and molecular targets of tea polyphenol interventions in AD. In addition, the interaction mechanisms between hub targets and tea polyphenols were assessed via molecular docking. Overall, this research aimed to provide some insights into the precise target information for preventing and alleviating AD using tea polyphenols.

2. Materials and Methods

2.1. Prediction of AD-Related Targets and Tea Polyphenols Targets

First, we screened for potential AD target genes from the DisGeNET (https://www.disgenet.org/, accessed on 25 October 2022) [36], GeneCards (https://www.genecards.org/, accessed on 25 October 2022) [37], PharmGKB (https://www.pharmgkb.org/, accessed on 24 October 2022) [38] and UniProt (https://www.uniprot.org/, accessed on 25 October 2022) [39] databases. In total, we identified 220 potential AD target genes with a score > 0.1 in DisGeNET, 1300 potential targets with a score > 1 in GeneCards, and 20 potential targets in PharmGKB. Second, after the union of the three databases was deleted, 1407 potential AD target genes remained. Then, we used the SEA (http://sea.bkslab.org/, accessed on 20 November 2022) [40] and Super-Pred [41] (https://prediction.charite.de/subpages/target_prediction.php, accessed on 20 November 2022) databases for predicting the target genes of EC, ECG, EGC and EGCG based on the intersection of active components and disease target genes, which yielded 46, 12, 43 and 57 related intersection genes, respectively.

2.2. Construction of the Protein–Protein Interaction (PPI) Network

The PPI network was constructed using the STRING database (http://string-db.org/, accessed on 22 November 2022) [42] to assess the potential interactions between the screened hub targets. The interactions between hub targets were subsequently displayed using Cytoscape software (version 3.9.1; https://cytoscape.org/, accessed on 22 November 2022) [43]. Then, the topological characteristics of the PPI networks were analyzed, and the top 10 hub genes were selected using the analytical tool of Cytoscape.

2.3. GO and KEGG Enrichment Analysis

R packages such as BiocManager, clusterProfiler, AnnotationHub, org.Hs.eg, pathview, dplyr and ggplot2 were used for enrichment analysis of Gene Ontology (GO) [44,45] biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) according to the core target information. Using a cut-off of p = 0.01 and q = 0.01, we retrieved GO information from org.Hs.eg.Db of Bioconductor. The final results were visualized using bar charts and bubble charts.

2.4. Quantum Chemical Calculation

The quantitative calculation of the four tea polyphenols was performed by Gaussian09W and GaussView 5.0 [46]. The Method of Gaussian Calculation was B3LYP of DFT in Ground State, and we made the Basis Set 6–31G. Visualizations of the quantitative calculations were mapped by Multiwfn [47] and VMD [48], including HOMO-LUMO orbits, electrostatic potential (ESP), average local ionization energy (ALIE) and local electron affinity (LEA).

2.5. Complex Fingerprint Analysis

Discovery Studio was used to evaluate the interaction between the four tea polyphenols and the hub targets. On the basis of the results of the PPI analysis (intersection of the top 10 hub targets with high degree values), the crystal structure of VEGFA (4qaf, resolution: 1.80 Å) was chosen as the receptor protein from the RCSB protein data bank (http://www.rcsb.org/pdb, accessed on 24 November 2022) [49] for further molecular docking. The filtering criteria for selecting reporter proteins were organism “Homo” and “Resolution < 2.0”. Before docking, ligands and water molecules in the crystal structure of VEGFA were removed to prepare the VEGFA protein. Since there was no crystal structure for VEGFA with active small molecules, the active sites of VEGFA binding with peptides were selected to define the molecular docking sites. Then, the four kinds of tea polyphenols were used as ligand docking. Before docking, the energy of all small molecules was minimized by preparing small molecules and adding a CHARMm force field [50]. Additionally, batch docking was performed between the four tea polyphenols and VEGFA using LibDock [51]. The hydrogen bonds and coordinating interactions between the residues of receptor protein’s active sites and the tea polyphenols’ poses were identified using Discovery Studio [52] to conduct complex fingerprint analysis. Lastly, Pymol software [53] was used to show the details of the interaction between the tea polyphenols targets.

2.6. Alanine Scanning

The protein structures of tea polyphenols docking with VEGFA were imported into Discovery Studio and CHARMm force field [50]. We selected 3 Å amino acid residues around the ligands (four tea polyphenol small molecules) for single-point alanine mutation, and the binding energy after the mutation was calculated to screen key residues.

3. Results

Taking ECG as an example, the workflow for investigating the anti-AD-related mechanism of tea polyphenols using network pharmacological methods is shown in Figure 1. First, we collected and compared the retrieved gene data between tea polyphenols and AD from different online databases such as Super-Pred [41], DisGeNET [36], GeneCards [37], and others. Then, based on the cross-genes data, bioinformatics analysis was conducted to reveal the potential significance of tea polyphenols on AD, including underlying biological processes, pathways and mechanisms. Quantitative calculation and analysis of the four tea polyphenol small molecules were performed to explore their characteristics using Gaussian 09. Moreover, Discovery Studio was used to perform molecular docking and alanine scanning between the main targeting protein (VEGFA) and the four active components.

3.1. Potential Targets of AD and Tea Polyphenols

We collected 1407 pathogenic genes/targets related to AD from the DisGeNET, GeneCards and PharmGKB databases. In addition, regarding the 134, 39, 125 and 149 pharmacological genes/targets of EC, ECG, EGC and EGCG that were initially detected, respectively, Venn diagrams revealed that 46, 12, 43 and 57 genes/targets of these respective tea polyphenols were significantly associated with AD (Figure 2). The PPI networks, including the shared targets, are mapped in Figure 3.

3.2. Hub Targets Collection of Tea Polyphenols Anti-AD

Using cytoHubba, a functionally relevant protein network of the tea polyphenol–AD system was created by applying a topological analysis method from Maximal Clique Centrality (MCC) [54]. Scores for estimating the relationship between nodes and edges were obtained using the MCC algorithm, whereby a higher score and darker color indicated a more significant correlation of the gene with AD. Then, we screened the top 10 target genes/proteins with the highest scores for each active ingredient. The important proteins detected included GRM5, CYP3A4, ACE, NOS3, SERPINE1, CASP8, CTSD, ESR1, ESR2, VEGFA, PRKCA, PRKCB, PRKCD, ABCB1, PGF, MAPK14, CASP8, DRD2, DRD1, GRIN1, CDK5, APP, STAT1, TLR4 and MAPT (Figure 4).

3.3. GO and KEGG Pathway Enrichment Analysis

The cross-genes of tea polyphenols and AD were used for the enrichment analysis of the GO and KEGG pathways. The calculated data was demonstrated as bubble charts and histograms derived from GO and KEGG (Figure 5, Figure 6, Figure 7 and Figure 8).
Response to xenobiotic stimulus, response to ethanol, regulation of chemotaxis, response to alcohol, second-messenger-mediated signaling, positive regulation of chemotaxis, positive regulation of leukocyte chemotaxis, phospholipase C-activating G protein-coupled receptor signaling pathway, regulation of leukocyte chemotaxis and positive regulation of leukocyte migration were identified as potentially relevant biological processes related to the core targets of EC (Figure 5). The parts of enriched cell components included synaptic membrane, membrane raft, postsynaptic membrane, membrane microdomain, secretory granule lumen, integral component of synaptic membrane, intrinsic component of synaptic membrane, intrinsic component of presynaptic membrane and caveola (Figure 5). Additionally, the following molecular functions were identified by GO enrichment analysis: flavin adenine dinucleotide binding, steroid binding, neurotransmitter receptor activity and others (Figure 5). The enrichment pathways identified following KEGG analysis that contained the most core targets (p < 0.05) included cocaine addiction, calcium signaling pathway, arginine biosynthesis, HIF-1 signaling pathway, pathways of neurodegeneration-multiple diseases, estrogen signaling pathway, chemical carcinogenesis-receptor activation, AD, complement and coagulation cascade, Gap junction and others (Figure 5).
Peptidyl-serine phosphorylation, peptidyl-serine modification, peptidyl-threonine phosphorylation, peptidyl-threonine modification, positive regulation of angiogenesis, positive regulation of vasculature development, regulation of angiogenesis, regulation of vasculature development, vascular endothelial growth factor receptor signaling pathway and cell aging were identified as biological processes related to the core targets of ECG (Figure 6). The parts of cell components that were enriched included cytoplasmic vesicle lumen, vesicle lumen and secretory granule lumen (Figure 6). Additionally, the following molecular functions were identified by GO enrichment analysis: protein serine kinase activity, protein serine/threonine kinase activity, calcium-dependent protein kinase C activity and others (Figure 6). The enrichment pathways identified following KEGG analysis that contained the most core targets (p < 0.05) included the AGE-RAGE signaling pathway in diabetic complications, HIF-1 signaling pathway, VEGF signaling pathway, EGFR tyrosine kinase inhibitor resistance, focal adhesion and more (Figure 6).
Response to xenobiotic stimulus, phospholipase C-activating G protein-coupled receptor signaling, positive regulation of chemotaxis and others were identified as the biological processes related to the core targets of EGC (Figure 7). The parts of enriched cell components included synaptic membrane, postsynaptic membrane, membrane raft and more (Figure 7). Additionally, the following molecular functions were identified by GO enrichment analysis: neurotransmitter receptor activity, postsynaptic neurotransmitter receptor activity and others (Figure 7). The enrichment pathways identified following KEGG analysis that contained the most core targets (p < 0.05) included cocaine addiction, gap junction, alcoholism, neuroactive ligand-receptor interaction, dopaminergic synapse, AD, complement and coagulation cascades, and calcium signaling pathway (Figure 7).
Response to xenobiotic stimulus, regulation of body fluid levels, cellular response to peptide, peptidyl-serine phosphorylation, ERK1 and ERK2 cascade and others were identified as the biological processes related to the core targets of EGCG (Figure 8). The enriched parts of cell components included the synaptic membrane, postsynaptic membrane, cytoplasmic vesicle lumen and so on (Figure 8). Additionally, the following molecular functions were identified by GO enrichment analysis: protein serine kinase activity, protein serine/threonine kinase activity, neurotransmitter receptor activity and others (Figure 8). The enrichment pathways identified following KEGG analysis that contained the most core targets (p < 0.05) included the AGE-RAGE signaling pathway in diabetic complications, HIF-1 signaling pathway, calcium signaling pathway, pathways of neurodegeneration-multiple diseases and more (Figure 8).

3.4. Quantum Chemical Calculation of Four Tea Polyphenols

The B3LYP/6–31G* method was used to perform the Gaussian quantification calculation of the four tea polyphenols. First, the calculation results of the HOMO–LUMO orbit (Figure 9) were: (1) EC: HOMO orbit energy = −5.53 eV, LUMO orbit energy = −0.15 eV, and energy gap = 5.38 eV; (2) ECG: HOMO orbit energy = −5.63 eV, LUMO orbit energy = −1.16 eV, and energy gap = 4.47 eV; (3) EGC: HOMO orbit energy = −5.58 eV, LUMO orbit energy = 0.08 eV, and energy gap = 5.66 eV; and (4) EGCG HOMO orbit energy = −5.47 eV, LUMO orbit energy = −1.05 eV, and energy gap = 4.42 eV. Next, the results of the electrostatic potential, local electron affinity energy and average local ionization energy diagram (Figure 10) of the Gauss calculation indicated that the four tea polyphenols molecules were closely bound to VEGFA.

3.5. Binding of Four Tea Polyphenols to VEGFA

The pre-docking protein of VEGFA, the intersection protein of the top 10 key proteins between four tea polyphenols and AD, was identified using the Uniprot and protein data bank databases. Then, the compound structure with PDB ID 4QAF was determined and used for molecular docking with the four tea polyphenols. Since VEGFA had no effective small-molecule-binding crystal structure, we estimated the binding site of the tea polyphenols and VEGFA according to the polypeptide’s binding site. Using the information on active sites in the structure of 4QAF protein, we determined the active sites based on the positions of C: TYR25, D: TYR45, ARG82, ILE83, PRO85, HIS86, GLY88, GLN89 and HIS90. In VEGFA (4QAF), we set the input site sphere parameter to 2.27147, 58.0352, 9.31752 and 15.027 (the coordinates and radius of the sphere), accompanied by 1.80 Å RMSD in the original protein. The conventional hydrogen bonds between EC and amino acid residues were PHE36, SER50 and PHE47, and the carbon-hydrogen bonds between them were LYS107 and GLU64. The conventional hydrogen bonds between ECG and amino acid residues were PHE47, LYS48, LEU66, ASP63 and CYS68, and the carbon-hydrogen bonds between them were LYS107, GLU64, GLU67 and ASP34. The conventional hydrogen bonds between EGC and amino acid residues were SER50 and PHE47, and the carbon-hydrogen bonds between them were LYS107 and GLU64. The conventional hydrogen bonds between EGCG and amino acid residues were CYS68, GLY59, CYS61, ASN62 and ASP63, and the carbon-hydrogen bonds between them were ASP34 and LEU66. According to the compound fingerprint analysis, the common residues of the three tea polyphenols EC, ECG and EGC were GLU64, LYS107, PHE36 and PHE47 (Figure 11). Overall, these findings suggested that these residues could be the potential key residues of green tea acting on AD, while EGCG might be dissimilar to the other three tea polyphenols due to structural problems.

3.6. Alanine Scanning of the Binding Sites

After alanine scanning, we discovered that the key residues of EC for VEGFA might be GLU64 and PHE36 (Table 1), the key residues of ECG for target protein were GLU64, PHE36, CYS61 and LYS48 (Table 2), the key residues of EGC for target protein were GLU64, PHE36 and SER50 (Table 3), and the key residues of EGCG for target protein were GLU64 and LYS48 (Table 4).

4. Discussion

In this study, network pharmacological analysis was conducted to reveal the biological processes, pathways and mechanisms of four tea polyphenol active molecules against AD [55]. The bioinformatics research results revealed that the core intersection target was VEGFA. Molecular docking analysis and quantitative analysis of four kinds of tea polyphenols revealed the binding activity of the four kinds of tea polyphenols with VEGFA structure in AD, indicating that EC, ECG and EGC could effectively bind to specific proteins in patients with AD, as well as the key residues of interaction by combining alanine scanning. VEGFA has important functions, such as directly regulating the various ion channels on neuronal cell membranes, the transmission of excitatory and inhibitory neurotransmitters, and the development and regeneration of neurons. The neuroprotective effects of VEGFA include reducing the degree of ischemic brain injury, reducing the death of nerve cells in the damaged brain, narrowing the foci of cerebral infarction, etc. In addition, in the case of brain injury, VEGFA promotes the transformation of glial cells into neurons, and functions as an important regulatory protein in the structural and functional remodeling of neurovascular units [56,57]. For the selected key target gene VEGFA, on the one hand, relevant experiments have proved that decreased levels of VEGFA in serum and cerebrospinal fluid are linked with increased risk for AD and cognitive impairments [58,59], while on the other hand, it has been reported that EGCG could inhibit wild-type EGFR as well as some of its mutated forms [60]. Moreover, it has been shown that green tea, black tea and oolong tea polyphenols could increase the gene expression of VEGFA [61].
We investigated the potential role of four tea polyphenols in the treatment of AD by assessing their effects on different biological processes and molecular functions related to AD. GO bio-processes of the four tea polyphenols emphasized the response to xenobiotic stimuli, including ADAM17, MDK, TP53, STAT1 and more. ADAM17 is a transmembrane metalloproteinase involved in the shedding of extracellular domains of various proteins, and has the characteristics of adhesion and proteolysis. TNF-α plays a key role in processing many other substrates, such as cell adhesion molecules, cytokines, growth factor receptors and epidermal growth factor receptors (EGFR), and in activating the Notch signaling pathway [62]. γ-Secretase is an important cleaving enzyme that activates the Notch pathway. It is also a cleaving enzyme of amyloid precursor protein (APP) related to AD. Midkine (MK or MDK) is a 15 kDa heparin-binding molecule known as neurite growth-promoting factor-2 (NEGF2). The nervous system is an essential part of the human body, and the repair and regeneration of injured axons are of great significance for maintaining the function of the nervous system, and are closely related to neurodegenerative diseases. The regenerative ability of the peripheral nervous system (PNS) differs from that of the central nervous system (CNS). The axons of the peripheral nervous system can often regenerate themselves after being damaged to a certain extent, while the axons of the central nervous system are difficult to recover after damage. The p53 protein is directly involved in the formation of AD. The transcription factor STAT1 regulates the type I interferon signaling pathway in SCD, and the down-regulation of interferon signaling activity might increase the risk of AD progression [63]. Here, our data showed that tea polyphenols might be an alternative treatment for AD. In regard to molecular functions, we discovered that tea polyphenols regulated the activities of protein serine kinase, neuron transmitter–receivers and others in AD.
Our results also indicated that the four tea polyphenols could exert their anti-AD effects through the calcium signaling pathway, which is one of the main signaling pathways in neurodegenerative diseases. It had previously been confirmed that an increase in calcium ion and cAMP levels promoted axon regeneration [64]. Additionally, it had been reported that green tea polyphenols facilitated Ca2+-dependent glutamate release [65]. Apart from calcium signals, the results of our KEGG analysis indicated the potential implications of many nerve-related signals, including the HIF-1 signaling pathway, AGE–RAGE signaling pathway in diabetic complications, MAPK signaling pathway and neurodegenerative disease pathway. The expression of HIF-1 could induce the accumulation of the p53 protein [66], which participates in the formation of AD. A previous study also showed that a prodrug of EGCG (pro-EGCG) alleviated mouse laser-induced choroidal neovascularization (CNV) leakage and reduced CNV area by down-regulating the HIF-1α/VEGF/VEGFR2 pathway [67]. Green tea polyphenols can down-regulate caveolin-1 expression via ERK1/2 and p38MAPK in endothelial cells [68]. Advanced glycation end products (AGEs)-receptor of advanced glycation end products (RAGE) signaling pathway is an important link in the occurrence and development of diabetic nephropathy, whose mechanism of action is mainly to activate the transcription of nuclear factor-κB (NF-κB) and stimulate the production of vascular endothelial growth factor (VEGF) [69], proving that VEGFA is a key target protein for the interaction between AD and tea polyphenols.
Overall, this study revealed that the four tea polyphenols mainly showed their anti-AD mitigation effects through responses to xenobiotic stimulus. In addition, bioinformatics analysis showed that the investigated tea polyphenols affected AD via calcium channels, HIF-1 channels and others. Lastly, our analyses also revealed the promising role of VEGFA as a potential biomarker for diagnosing AD.

5. Conclusions

By assessing the enrichment of intersection genes in AD, we revealed that tea polyphenols exerted their anti-AD effects via the calcium signaling and neurodegenerative disease signaling pathways. VEGFA was the common key target protein of the four tea polyphenol molecules, and Glu64 and Phe36 were identified as the key residues of interaction. In conclusion, using network pharmacological analysis, we comprehensively revealed the biological processes, targets and molecular mechanisms of EC, EGC, ECG and EGCG in AD, and showed that they could serve as promising compounds for treating AD.

Author Contributions

M.W.: conceptualization, methodology, supervision, investigation, writing—original draft, writing—review and editing; X.Y.: writing—original draft, data curation, methodology, formal analysis, software, visualization; Y.G.: conceptualization. W.H.: resources, formal analysis, methodology, project administration, funding acquisition. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Overseas Cooperation Project of Jilin Province (grant number: 20200801069GH).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data are available from the corresponding author.

Conflicts of Interest

The authors declare that they have no known competing financial interest or personal relationships that could have appeared to influence the work reported in this paper.

References

  1. Jeremic, D.; Jimenez-Diaz, L.; Navarro-Lopez, J.D. Past, present and future of therapeutic strategies against amyloid-beta peptides in Alzheimer’s disease: A systematic review. Ageing Res. Rev. 2021, 72, 101496. [Google Scholar] [CrossRef]
  2. Pleen, J.; Townley, R. Alzheimer’s disease clinical trial update 2019–2021. J. Neurol. 2022, 269, 1038–1051. [Google Scholar] [CrossRef] [PubMed]
  3. Tatulian, S.A. Challenges and hopes for Alzheimer’s disease. Drug Discov. Today 2022, 27, 1027–1043. [Google Scholar] [CrossRef]
  4. Janoutova, J.; Machaczka, O.; Zatloukalova, A.; Janout, V. Is Alzheimer’s disease a type 3 diabetes? A review. Cent. Eur. J. Public Health 2022, 30, 139–143. [Google Scholar] [CrossRef]
  5. Khan, S.; Barve, K.H.; Kumar, M.S. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Curr. Neuropharmacol. 2020, 18, 1106–1125. [Google Scholar] [CrossRef]
  6. Pakdin, M.; Toutounchian, S.; Namazi, S.; Arabpour, Z.; Pouladi, A.; Afsahi, S.; Poudineh, M.; Nasab, M.M.M.; Yaghoobpoor, S.; Deravi, N. Type 2 Diabetes Mellitus and Alzheimer’s Disease: A Review of the Potential Links. Curr. Diabetes Rev. 2022, 18, e051121197760. [Google Scholar] [CrossRef] [PubMed]
  7. Wang, H.; Lu, J.; Zhao, X.; Qin, R.; Song, K.; Xu, Y.; Zhang, J.; Chen, Y. Alzheimer’s disease in elderly COVID-19 patients: Potential mechanisms and preventive measures. Neurol. Sci. 2021, 42, 4913–4920. [Google Scholar] [CrossRef] [PubMed]
  8. Singh, B.; Singh, H.; Singh, B.; Kumar, N.; Rajput, A.; Sidhu, D.; Kaur, A.; Arora, S.; Kaur, S. A Comprehensive Review on Medicinal Herbs and Novel Formulations for the Prevention of Alzheimer’s Disease. Curr. Drug Deliv. 2022, 19, 212–228. [Google Scholar] [CrossRef]
  9. Lu, L.; Yu, X.; Cai, Y.; Sun, M.; Yang, H. Application of CRISPR/Cas9 in Alzheimer’s Disease. Front. Neurosci. 2021, 15, 803894. [Google Scholar] [CrossRef]
  10. Ouyang, F.; Jiang, Z.; Chen, X.; Chen, Y.; Wei, J.; Xing, S.; Zhang, J.; Fan, Y.; Zeng, J. Is Cerebral Amyloid-beta Deposition Related to Post-stroke Cognitive Impairment? Transl. Stroke Res. 2021, 12, 946–957. [Google Scholar] [CrossRef]
  11. Shi, M.; Chu, F.; Zhu, F.; Zhu, J. Impact of Anti-amyloid-beta Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Front. Aging Neurosci. 2022, 14, 870517. [Google Scholar] [CrossRef]
  12. Chen, D.; Liu, X.; Chen, Y.; Lin, H. Amyloid peptides with antimicrobial and/or microbial agglutination activity. Appl. Microbiol. Biotechnol. 2022, 106, 7711–7720. [Google Scholar] [CrossRef] [PubMed]
  13. Roda, A.R.; Serra-Mir, G.; Montoliu-Gaya, L.; Tiessler, L.; Villegas, S. Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease. Neural. Regen. Res. 2022, 17, 1666–1674. [Google Scholar] [CrossRef] [PubMed]
  14. Soto-Ospina, A.; Araque Marin, P.; Bedoya, G.J.; Villegas Lanau, A. Structural Predictive Model of Presenilin-2 Protein and Analysis of Structural Effects of Familial Alzheimer’s Disease Mutations. Biochem. Res. Int. 2021, 2021, 9542038. [Google Scholar] [CrossRef] [PubMed]
  15. Knorz, A.L.; Quante, A. Alzheimer’s Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review. J. Geriatr. Psychiatry Neurol. 2022, 35, 475–486. [Google Scholar] [CrossRef] [PubMed]
  16. Poudel, P.; Park, S. Recent Advances in the Treatment of Alzheimer’s Disease Using Nanoparticle-Based Drug Delivery Systems. Pharmaceutics 2022, 14, 835. [Google Scholar] [CrossRef] [PubMed]
  17. Zhang, R.; Zhang, L.; Li, Z.; Zhang, P.; Song, H.; Yao, D.A.; Cao, J.; Zhang, J.J. Green tea improves cognitive function through reducing AD-pathology and improving anti-oxidative stress capacity in Chinese middle-aged and elderly people. Front. Aging Neurosci. 2022, 14, 919766. [Google Scholar] [CrossRef]
  18. Amirpour, M.; Mirshekar, M.A.; Sedaghat, G.; Montazerifar, F.; Shourestani, S.; Arabmoazzen, S.; Naghizadeh, M. The effects of green tea on cognitive impairments in the rat model of Alzheimer’s disease: Protection against inflammatory and oxidative damage. Nutr. Neurosci. 2022, 25, 2659–2667. [Google Scholar] [CrossRef]
  19. Hou, Z.W.; Chen, C.H.; Ke, J.P.; Zhang, Y.Y.; Qi, Y.; Liu, S.Y.; Yang, Z.; Ning, J.M.; Bao, G.H. alpha-Glucosidase Inhibitory Activities and the Interaction Mechanism of Novel Spiro-Flavoalkaloids from YingDe Green Tea. J. Agric. Food Chem. 2022, 70, 136–148. [Google Scholar] [CrossRef]
  20. Bastianetto, S.; Yao, Z.X.; Papadopoulos, V.; Quirion, R. Neuroprotective effects of green and black teas and their catechin gallate esters against beta-amyloid-induced toxicity. Eur. J. Neurosci. 2006, 23, 55–64. [Google Scholar] [CrossRef]
  21. Wobst, H.J.; Sharma, A.; Diamond, M.I.; Wanker, E.E.; Bieschke, J. The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. FEBS Lett. 2015, 589, 77–83. [Google Scholar] [CrossRef] [PubMed]
  22. Kumar, V.; Gour, S.; Peter, O.S.; Gandhi, S.; Goyal, P.; Pandey, J.; Harsolia, R.S.; Yadav, J.K. Effect of Green Tea Polyphenol Epigallocatechin-3-gallate on the Aggregation of alphaA(66-80) Peptide, a Major Fragment of alphaA-crystallin Involved in Cataract Development. Curr. Eye Res. 2017, 42, 1368–1377. [Google Scholar] [CrossRef] [PubMed]
  23. Chen, T.; Yang, Y.; Zhu, S.; Lu, Y.; Zhu, L.; Wang, Y.; Wang, X. Inhibition of Abeta aggregates in Alzheimer’s disease by epigallocatechin and epicatechin-3-gallate from green tea. Bioorg. Chem. 2020, 105, 104382. [Google Scholar] [CrossRef] [PubMed]
  24. Chen, L.; Guo, Y.; Wu, Z.; Zhao, S.; Zhang, Z.; Zheng, F.; Sun, L.; Hao, Z.; Xu, C.; Wang, T.; et al. Epicatechin gallate prevents the de novo synthesis of fatty acid and the migration of prostate cancer cells. Acta Biochim. Biophys. Sin. 2021, 53, 1662–1669. [Google Scholar] [CrossRef]
  25. Yong, H.; Hu, H.; Wang, Z.; Yun, D.; Kan, J.; Liu, J. Structure, stability and antioxidant activity of dialdehyde starch grafted with epicatechin, epicatechin gallate, epigallocatechin and epigallocatechin gallate. J. Sci. Food Agric. 2022, 102, 6373–6386. [Google Scholar] [CrossRef]
  26. Chen, W.; Zhou, C.; Chen, J.; Wang, M.; Zhou, F.; Wang, C.; Zhang, X.; Zhou, W. Design and synthesis of epigallocatechin (EGC) analogs selective to inhibit alpha-amylase over alpha-glucosidases via the incorporation of caffeine acid and its derivatives. Bioorg. Chem. 2022, 119, 105515. [Google Scholar] [CrossRef] [PubMed]
  27. da Silva-Junior, E.F.; Silva, L.R. Multi-target Approaches of Epigallocatechin-3-O-gallate (EGCG) and its Derivatives against Influenza Viruses. Curr. Top Med. Chem. 2022, 22, 1485–1500. [Google Scholar] [CrossRef]
  28. Butterfield, D.; Castegna, A.; Pocernich, C.; Drake, J.; Scapagnini, G.; Calabrese, V. Nutritional approaches to combat oxidative stress in Alzheimer’s disease. J. Nutr. Biochem. 2002, 13, 444. [Google Scholar] [CrossRef]
  29. Higdon, J.V.; Frei, B. Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Crit. Rev. Food Sci. Nutr. 2003, 43, 89–143. [Google Scholar] [CrossRef]
  30. Weinreb, O.; Mandel, S.; Amit, T.; Youdim, M.B. Neurological mechanisms of green tea polyphenols in Alzheimer’s and Parkinson’s diseases. J. Nutr. Biochem. 2004, 15, 506–516. [Google Scholar] [CrossRef]
  31. Surguchov, A.; Bernal, L.; Surguchev, A.A. Phytochemicals as Regulators of Genes Involved in Synucleinopathies. Biomolecules 2021, 11, 624. [Google Scholar] [CrossRef] [PubMed]
  32. Ono, K.; Yoshiike, Y.; Takashima, A.; Hasegawa, K.; Naiki, H.; Yamada, M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: Implications for the prevention and therapeutics of Alzheimer’s disease. J. Neurochem. 2003, 87, 172–181. [Google Scholar] [CrossRef] [PubMed]
  33. Wang, J.S.; Gong, X.F.; Feng, J.L.; Li, H.S.; Li, X.; Deng, S.; Ren, P.Z.; Wang, J.M.; Lv, M.S.; Jin, R.F.; et al. Study on the Mechanism of Jiawei Shengjiang Powder in Improving Male Asthma-Induced Asthenospermia Based on Network Pharmacology and Bioinformatics. Drug Des. Devel. Ther. 2021, 15, 1245–1259. [Google Scholar] [CrossRef]
  34. Nguyen, N.H.; Fumery, M.; Dulai, P.S.; Prokop, L.J.; Sandborn, W.J.; Murad, M.H.; Singh, S. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: A systematic review and network meta-analyses. Lancet Gastroenterol. Hepatol. 2018, 3, 742–753. [Google Scholar] [CrossRef] [PubMed]
  35. Duan, H.; Khan, G.J.; Shang, L.J.; Peng, H.; Hu, W.C.; Zhang, J.Y.; Hua, J.; Cassandra, A.; Rashed, M.M.A.; Zhai, K.F. Computational pharmacology and bioinformatics to explore the potential mechanism of Schisandra against atherosclerosis. Food Chem. Toxicol. 2021, 150, 112058. [Google Scholar] [CrossRef]
  36. Pinero, J.; Ramirez-Anguita, J.M.; Sauch-Pitarch, J.; Ronzano, F.; Centeno, E.; Sanz, F.; Furlong, L.I. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020, 48, D845–D855. [Google Scholar] [CrossRef]
  37. Stelzer, G.; Rosen, N.; Plaschkes, I.; Zimmerman, S.; Twik, M.; Fishilevich, S.; Stein, T.I.; Nudel, R.; Lieder, I.; Mazor, Y.; et al. The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr. Protoc. Bioinform. 2016, 54, 1.30.1–1.30.33. [Google Scholar] [CrossRef]
  38. Whirl-Carrillo, M.; Huddart, R.; Gong, L.; Sangkuhl, K.; Thorn, C.F.; Whaley, R.; Klein, T.E. An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine. Clin. Pharmacol. Ther. 2021, 110, 563–572. [Google Scholar] [CrossRef]
  39. UniProt, C. UniProt: The universal protein knowledgebase in 2021. Nucleic Acids Res. 2021, 49, D480–D489. [Google Scholar] [CrossRef]
  40. Keiser, M.J.; Roth, B.L.; Armbruster, B.N.; Ernsberger, P.; Irwin, J.J.; Shoichet, B.K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 2007, 25, 197–206. [Google Scholar] [CrossRef] [Green Version]
  41. Nickel, J.; Gohlke, B.O.; Erehman, J.; Banerjee, P.; Rong, W.W.; Goede, A.; Dunkel, M.; Preissner, R. SuperPred: Update on drug classification and target prediction. Nucleic Acids Res. 2014, 42, W26–W31. [Google Scholar] [CrossRef] [PubMed]
  42. Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P.; et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019, 47, D607–D613. [Google Scholar] [CrossRef]
  43. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498–2504. [Google Scholar] [CrossRef] [PubMed]
  44. Ashburner, M.; Ball, C.A.; Blake, J.A.; Botstein, D.; Butler, H.; Cherry, J.M.; Davis, A.P.; Dolinski, K.; Dwight, S.S.; Eppig, J.T.; et al. Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25, 25–29. [Google Scholar] [CrossRef] [PubMed]
  45. The Gene Ontology Consortium. The Gene Ontology resource: Enriching a GOld mine. Nucleic Acids Res. 2021, 49, D325–D334. [Google Scholar] [CrossRef] [PubMed]
  46. Hosseini, S.; Ketabi, S.; Hasheminasab, G. QSAR study of antituberculosis activity of oxadiazole derivatives using DFT calculations. J. Recept Signal Transduct Res. 2022, 42, 503–511. [Google Scholar] [CrossRef]
  47. Lu, T.; Chen, F. Multiwfn: A multifunctional wavefunction analyzer. J. Comput. Chem. 2012, 33, 580–592. [Google Scholar] [CrossRef]
  48. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 1996, 14, 33. [Google Scholar] [CrossRef]
  49. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235–242. [Google Scholar] [CrossRef]
  50. Brooks, B.R.; Brooks, C.L., 3rd; Mackerell, A.D., Jr.; Nilsson, L.; Petrella, R.J.; Roux, B.; Won, Y.; Archontis, G.; Bartels, C.; Boresch, S.; et al. CHARMM: The biomolecular simulation program. J. Comput. Chem. 2009, 30, 1545–1614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Rao, S.N.; Head, M.S.; Kulkarni, A.; LaLonde, J.M. Validation studies of the site-directed docking program LibDock. J. Chem. Inf. Model 2007, 47, 2159–2171. [Google Scholar] [CrossRef] [PubMed]
  52. Xie, Y.; Liu, Y.; Zheng, P.; Zhang, T.; Ye, X.; Liu, M.; Huang, M.; Wan, Q.; Zhang, J. Based on UPLC-Q-TOF-MS/MS, Systematic Network Pharmacology, and Molecular Docking to Explore the Potential Mechanism of Fructus Aurantii for Major Depression Disorder. Evid. Based Complement. Alternat. Med. 2021, 2021, 6486287. [Google Scholar] [CrossRef] [PubMed]
  53. Seeliger, D.; de Groot, B.L. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des 2010, 24, 417–422. [Google Scholar] [CrossRef] [PubMed]
  54. Wang, Y.; Zhang, X.; Duan, M.; Zhang, C.; Wang, K.; Feng, L.; Song, L.; Wu, S.; Chen, X. Identification of Potential Biomarkers Associated with Acute Myocardial Infarction by Weighted Gene Coexpression Network Analysis. Oxid. Med. Cell. Longev. 2021, 2021, 5553811. [Google Scholar] [CrossRef] [PubMed]
  55. Li, R.; Yu, S.Z.; Liang, X.; Li, Y.; Lai, K.P. Vitamin C exerts anti-cadmium induced fracture functions/targets: Bioinformatic and biostructural findings. Food Sci. Hum. Wellness 2022, 11, 1384–1391. [Google Scholar] [CrossRef]
  56. Gabrilovich, D.; Ishida, T.; Oyama, T.; Ran, S.; Kravtsov, V.; Nadaf, S.; Carbone, D.P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998, 92, 4150–4166. [Google Scholar] [CrossRef]
  57. Alfaro, C.; Suarez, N.; Gonzalez, A.; Solano, S.; Erro, L.; Dubrot, J.; Palazon, A.; Hervas-Stubbs, S.; Gurpide, A.; Lopez-Picazo, J.M.; et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br. J. Cancer 2009, 100, 1111–1119. [Google Scholar] [CrossRef]
  58. Huang, L.; Jia, J.; Liu, R. Decreased serum levels of the angiogenic factors VEGF and TGF-beta1 in Alzheimer’s disease and amnestic mild cognitive impairment. Neurosci. Lett. 2013, 550, 60–63. [Google Scholar] [CrossRef]
  59. Hohman, T.J.; Bell, S.P.; Jefferson, A.L.; Alzheimer’s Disease Neuroimaging, I. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: Exploring interactions with biomarkers of Alzheimer disease. JAMA Neurol. 2015, 72, 520–529. [Google Scholar] [CrossRef]
  60. Minnelli, C.; Cianfruglia, L.; Laudadio, E.; Mobbili, G.; Galeazzi, R.; Armeni, T. Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer. Int. J. Mol. Sci. 2021, 22, 11833. [Google Scholar] [CrossRef]
  61. Heber, D.; Zhang, Y.; Yang, J.; Ma, J.E.; Henning, S.M.; Li, Z. Green tea, black tea, and oolong tea polyphenols reduce visceral fat and inflammation in mice fed high-fat, high-sucrose obesogenic diets. J. Nutr. 2014, 144, 1385–1393. [Google Scholar] [CrossRef] [PubMed]
  62. Ando, K.; Kanazawa, S.; Tetsuka, T.; Ohta, S.; Jiang, X.; Tada, T.; Kobayashi, M.; Matsui, N.; Okamoto, T. Induction of Notch signaling by tumor necrosis factor in rheumatoid synovial fibroblasts. Oncogene 2003, 22, 7796–7803. [Google Scholar] [CrossRef] [PubMed]
  63. Song, L.; Chen, J.; Lo, C.Z.; Guo, Q.; Consortium, Z.I.B.; Feng, J.; Zhao, X.M. Impaired type I interferon signaling activity implicated in the peripheral blood transcriptome of preclinical Alzheimer’s disease. EBioMedicine 2022, 82, 104175. [Google Scholar] [CrossRef] [PubMed]
  64. Ghosh-Roy, A.; Wu, Z.; Goncharov, A.; Jin, Y.; Chisholm, A.D. Calcium and cyclic AMP promote axonal regeneration in Caenorhabditis elegans and require DLK-1 kinase. J. Neurosci. 2010, 30, 3175–3183. [Google Scholar] [CrossRef]
  65. Chou, C.W.; Huang, W.J.; Tien, L.T.; Wang, S.J. (-)-Epigallocatechin gallate, the most active polyphenolic catechin in green tea, presynaptically facilitates Ca2+-dependent glutamate release via activation of protein kinase C in rat cerebral cortex. Synapse 2007, 61, 889–902. [Google Scholar] [CrossRef]
  66. Schmid, T.; Zhou, J.; Brune, B. HIF-1 and p53: Communication of transcription factors under hypoxia. J. Cell. Mol. Med. 2004, 8, 423–431. [Google Scholar] [CrossRef]
  67. Xu, J.; Tu, Y.; Wang, Y.; Xu, X.; Sun, X.; Xie, L.; Zhao, Q.; Guo, Y.; Gu, Y.; Du, J.; et al. Prodrug of epigallocatechin-3-gallate alleviates choroidal neovascularization via down-regulating HIF-1alpha/VEGF/VEGFR2 pathway and M1 type macrophage/microglia polarization. Biomed. Pharmacother. 2020, 121, 109606. [Google Scholar] [CrossRef]
  68. Li, Y.; Ying, C.; Zuo, X.; Yi, H.; Yi, W.; Meng, Y.; Ikeda, K.; Ye, X.; Yamori, Y.; Sun, X. Green tea polyphenols down-regulate caveolin-1 expression via ERK1/2 and p38MAPK in endothelial cells. J. Nutr. Biochem. 2009, 20, 1021–1027. [Google Scholar] [CrossRef]
  69. Chen, Y.J.; Chan, D.C.; Chiang, C.K.; Wang, C.C.; Yang, T.H.; Lan, K.C.; Chao, S.C.; Tsai, K.S.; Yang, R.S.; Liu, S.H. Advanced glycation end-products induced VEGF production and inflammatory responses in human synoviocytes via RAGE-NF-kappaB pathway activation. J. Orthop. Res. 2016, 34, 791–800. [Google Scholar] [CrossRef] [Green Version]
Figure 1. Workflow of the network pharmacology methods demonstrated the core targets and molecular mechanism related to the activity of tea polyphenols on treating AD. It contained the databases screening, PPI network mapping, target gene identification, GO and KEGG pathway enrichment analysis, quantum chemical calculation, and molecular docking.
Figure 1. Workflow of the network pharmacology methods demonstrated the core targets and molecular mechanism related to the activity of tea polyphenols on treating AD. It contained the databases screening, PPI network mapping, target gene identification, GO and KEGG pathway enrichment analysis, quantum chemical calculation, and molecular docking.
Foods 12 00635 g001
Figure 2. Venn diagrams showing the cross-genes shared between tea polyphenols and AD. (A) The number of common genes shared between EC and AD is 46. (B) The number of common genes shared between ECG and AD is 12. (C) The number of common genes shared between EGC and AD is 43. (D) The number of common genes shared between EGCG and AD is 57.
Figure 2. Venn diagrams showing the cross-genes shared between tea polyphenols and AD. (A) The number of common genes shared between EC and AD is 46. (B) The number of common genes shared between ECG and AD is 12. (C) The number of common genes shared between EGC and AD is 43. (D) The number of common genes shared between EGCG and AD is 57.
Foods 12 00635 g002
Figure 3. PPI network analysis using STRING database demonstrating the interaction of the shared genes found in tea polyphenols and AD. (A) PPI network of EC. (B) PPI network of ECG. (C) PPI network of EGC. (D) PPI network of EGCG.
Figure 3. PPI network analysis using STRING database demonstrating the interaction of the shared genes found in tea polyphenols and AD. (A) PPI network of EC. (B) PPI network of ECG. (C) PPI network of EGC. (D) PPI network of EGCG.
Foods 12 00635 g003
Figure 4. Protein interaction involved in the anti-AD activity of tea polyphenols. (A) The interaction of core targets of EC. (B) The interaction of core targets of ECG. (C) The interaction of core targets of EGC. (D) The interaction of core targets EGCG. Using cytoHubba, the interaction of hub targets related to the activity of tea polyphenols on treating AD was shown. By intersecting top10 hub genes, we understood that the key protein was VEGFA.
Figure 4. Protein interaction involved in the anti-AD activity of tea polyphenols. (A) The interaction of core targets of EC. (B) The interaction of core targets of ECG. (C) The interaction of core targets of EGC. (D) The interaction of core targets EGCG. Using cytoHubba, the interaction of hub targets related to the activity of tea polyphenols on treating AD was shown. By intersecting top10 hub genes, we understood that the key protein was VEGFA.
Foods 12 00635 g004
Figure 5. Results of GO and KEGG pathway enrichment analysis based on the common genes between EC and AD. The visualization of GO analysis related to EC against AD including biological processes, molecular functions and cellular components. Results of KEGG pathway enrichment analysis of the intersecting genes of EC and AD. The adjusted p-value is implied by the color of bar; and the bubble size means the number of genes.
Figure 5. Results of GO and KEGG pathway enrichment analysis based on the common genes between EC and AD. The visualization of GO analysis related to EC against AD including biological processes, molecular functions and cellular components. Results of KEGG pathway enrichment analysis of the intersecting genes of EC and AD. The adjusted p-value is implied by the color of bar; and the bubble size means the number of genes.
Foods 12 00635 g005
Figure 6. Results of GO and KEGG pathway enrichment analysis based on the common genes between ECG and AD. The visualization of GO analysis related to ECG against AD including biological processes, molecular functions and cellular components. Results of KEGG pathway enrichment analysis of the intersecting genes of ECG and AD. The adjusted p-value is implied by the color of bar; and the bubble size means the number of genes.
Figure 6. Results of GO and KEGG pathway enrichment analysis based on the common genes between ECG and AD. The visualization of GO analysis related to ECG against AD including biological processes, molecular functions and cellular components. Results of KEGG pathway enrichment analysis of the intersecting genes of ECG and AD. The adjusted p-value is implied by the color of bar; and the bubble size means the number of genes.
Foods 12 00635 g006
Figure 7. Results of GO and KEGG pathway enrichment analysis based on the common genes between EGC and AD. The visualization of GO analysis related to EGC against AD including biological processes, molecular functions and cellular components. Results of KEGG pathway enrichment analysis of the intersecting genes of EGC and AD. The adjusted p-value is implied by the color of bar; and the bubble size means the number of genes.
Figure 7. Results of GO and KEGG pathway enrichment analysis based on the common genes between EGC and AD. The visualization of GO analysis related to EGC against AD including biological processes, molecular functions and cellular components. Results of KEGG pathway enrichment analysis of the intersecting genes of EGC and AD. The adjusted p-value is implied by the color of bar; and the bubble size means the number of genes.
Foods 12 00635 g007
Figure 8. Results of GO and KEGG pathway enrichment analysis based on the common genes between EGCG and AD. The visualization of GO analysis related to EGCG against AD including biological processes, molecular functions and cellular components. Results of KEGG pathway enrichment analysis of the intersecting genes of EGCG and AD. The adjusted p-value is implied by the color of bar; and the bubble size means the number of genes.
Figure 8. Results of GO and KEGG pathway enrichment analysis based on the common genes between EGCG and AD. The visualization of GO analysis related to EGCG against AD including biological processes, molecular functions and cellular components. Results of KEGG pathway enrichment analysis of the intersecting genes of EGCG and AD. The adjusted p-value is implied by the color of bar; and the bubble size means the number of genes.
Foods 12 00635 g008
Figure 9. Molecular structure and HOMO–LUMO orbital diagram of four tea polyphenols. (A) The HOMO–LUMO orbital diagrams of EC. (B) The HOMO–LUMO orbital diagrams of ECG. (C) The HOMO–LUMO orbital diagrams of EGC. (D) The HOMO–LUMO orbital diagrams of EGCG.
Figure 9. Molecular structure and HOMO–LUMO orbital diagram of four tea polyphenols. (A) The HOMO–LUMO orbital diagrams of EC. (B) The HOMO–LUMO orbital diagrams of ECG. (C) The HOMO–LUMO orbital diagrams of EGC. (D) The HOMO–LUMO orbital diagrams of EGCG.
Foods 12 00635 g009
Figure 10. Electrostatic potential surface diagram of VEGFA, and the ESP diagrams, LEA diagrams and ALIE diagrams of the four tea polyphenols. (A) The ESP, LEA and ALIE diagrams of EC. (B) The ESP, LEA and ALIE diagrams of ECG. (C) The ESP, LEA and ALIE diagrams of EGC. (D) The ESP, LEA and ALIE diagrams of EGCG.
Figure 10. Electrostatic potential surface diagram of VEGFA, and the ESP diagrams, LEA diagrams and ALIE diagrams of the four tea polyphenols. (A) The ESP, LEA and ALIE diagrams of EC. (B) The ESP, LEA and ALIE diagrams of ECG. (C) The ESP, LEA and ALIE diagrams of EGC. (D) The ESP, LEA and ALIE diagrams of EGCG.
Foods 12 00635 g010
Figure 11. Complex fingerprint analysis of EC, ECG, EGC and EGCG (A) and molecular docking indicated the possible binding sites between AD and EC (B), ECG (C), and EGC (D). For EC, ECG and EGC, the key residues for target genes (VEGFA) may be GLU-64, LYS-107, PHE-36 and PHE-47.
Figure 11. Complex fingerprint analysis of EC, ECG, EGC and EGCG (A) and molecular docking indicated the possible binding sites between AD and EC (B), ECG (C), and EGC (D). For EC, ECG and EGC, the key residues for target genes (VEGFA) may be GLU-64, LYS-107, PHE-36 and PHE-47.
Foods 12 00635 g011
Table 1. Alanine scanning results of EC docking sites.
Table 1. Alanine scanning results of EC docking sites.
IndexMutationMutation Energy (kcal/mol)Effect
1S50A−0.23NEUTRAL
2C61A−0.01NEUTRAL
3E67A0.02NEUTRAL
4D63A0.03NEUTRAL
5L66A0.05NEUTRAL
6I35A0.23NEUTRAL
7F47A0.36NEUTRAL
8D34A0.41NEUTRAL
9E64A0.61DESTABILIZING
10F36A1.2DESTABILIZING
Table 2. Alanine scanning results of ECG docking sites.
Table 2. Alanine scanning results of ECG docking sites.
IndexMutationMutation Energy (kcal/mol)Effect
1E67A0NEUTRAL
2G59A0.01NEUTRAL
3C68A0.01NEUTRAL
4D63A0.03NEUTRAL
5L66A0.12NEUTRAL
6S50A0.36NEUTRAL
7C61A0.55DESTABILIZING
8F36A0.64DESTABILIZING
9K48A0.78DESTABILIZING
10E64A0.79DESTABILIZING
Table 3. Alanine scanning results of EGC docking sites.
Table 3. Alanine scanning results of EGC docking sites.
IndexMutationMutation Energy (kcal/mol)Effect
1S50A−0.58STABILIZING
2C61A−0.19NEUTRAL
3D63A−0.06NEUTRAL
4N62A−0.04NEUTRAL
5I46A0NEUTRAL
6E67A0.18NEUTRAL
7F47A0.28NEUTRAL
8D34A0.37NEUTRAL
9E64A0.53DESTABILIZING
10F36A0.98DESTABILIZING
Table 4. Alanine scanning results of EGCG docking sites.
Table 4. Alanine scanning results of EGCG docking sites.
IndexMutationMutation Energy (kcal/mol)Effect
1C61A−0.32NEUTRAL
2L66A−0.12NEUTRAL
3G59A−0.08NEUTRAL
4F47A−0.04NEUTRAL
5D63A0.02NEUTRAL
6I46A0.36NEUTRAL
7S50A0.45NEUTRAL
8D34A0.46NEUTRAL
9E64A0.61DESTABILIZING
10K48A0.84DESTABILIZING
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wang, M.; Yang, X.; Gao, Y.; Han, W. Computer-Aided Screening and Revealing Action Mechanism of Green Tea Polyphenols Intervention in Alzheimer’s Disease. Foods 2023, 12, 635. https://doi.org/10.3390/foods12030635

AMA Style

Wang M, Yang X, Gao Y, Han W. Computer-Aided Screening and Revealing Action Mechanism of Green Tea Polyphenols Intervention in Alzheimer’s Disease. Foods. 2023; 12(3):635. https://doi.org/10.3390/foods12030635

Chicago/Turabian Style

Wang, Min, Xiaotang Yang, Yilin Gao, and Weiwei Han. 2023. "Computer-Aided Screening and Revealing Action Mechanism of Green Tea Polyphenols Intervention in Alzheimer’s Disease" Foods 12, no. 3: 635. https://doi.org/10.3390/foods12030635

APA Style

Wang, M., Yang, X., Gao, Y., & Han, W. (2023). Computer-Aided Screening and Revealing Action Mechanism of Green Tea Polyphenols Intervention in Alzheimer’s Disease. Foods, 12(3), 635. https://doi.org/10.3390/foods12030635

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop